Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
PD98059
Cat. No.:
OB0225LY-0458
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Product Overview
Description:
PD98059 is a selective enzyme inhibitor primarily used to target MEK (mitogen-activated protein kinase kinase) in the MAPK/ERK signaling pathway.
Synonym:
PD 98059; 167869-21-8; 2-(2-Amino-3-methoxyphenyl)-4H-chromen-4-one; 2-(2-Amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 2-(2-Amino-3-methoxyphenyl)chromen-4-one
CAS No.:
167869-21-8
Compound CID:
4713
Formula:
C16H13NO3
Formula Weight:
267.28
Specification
Relative Density:
1.3 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
PD98059 can be used to study the MEK/ERK pathway in cell signaling pathways.
Library Information
Targets:
MAPKKs; Nuclear receptors
Receptors:
Aryl hydrocarbon receptor; ERK; MEK; MEK1
Pathways:
Autophagy; Immunology/Inflammation; MAPK
Plate Number:
AOCL-6
Plate Location:
h5
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
13.75 mg/mL; 51.44 mM
Ethanol Max Solubility:
1.3 mg/mL; 5 mM
Solubility:
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 0.67 mg/mL (2.51 mM)
ALogP:
2.373
HBA_Count:
3
HBD_Count:
1
Rotatable Bond:
2
